Aeras 402 Vaccine Protocol 003

Aeras 402 Vaccine Protocol 003

Phase I Double-Blind, Randomized, Placebo Controlled, Dose Escalation Study to Evaluate Safety and Immunogenicity of AERAS-402 in HIV-negative, BCG- Vaccinated Males and Females in South Africa Without Evidence of Tuberculosis.

Study Description:

The objective of the study is to test the safety and immunogenicity of the Aeras 402 vaccine.

The study used a double-blind, randomised, placebo-controlled dose escalation methodology, amongst 40 healthy adult subjects who were previously vaccinated with BCG.

The study timeline is between 2007 and 2008

PI: Greg Hussey

Partners: Aeras and Global TB Vaccine Foundation